Proteome Sciences (LON:PRM) Shares Down 2% – Should You Sell?

Proteome Sciences plc (LON:PRM) traded down 2% during mid-day trading on Thursday . The company traded as low as GBX 3.16 ($0.04) and last traded at GBX 3.48 ($0.04). 183,675 shares changed hands during trading, a decline of 11% from the average session volume of 205,581 shares. The stock had previously closed at GBX 3.55 ($0.05).

Proteome Sciences Trading Down 3.1 %

The company’s 50-day moving average is GBX 4.08 and its 200 day moving average is GBX 3.46. The company has a market cap of £10.15 million, a price-to-earnings ratio of -2.49 and a beta of 0.07. The company has a quick ratio of 0.37, a current ratio of 0.20 and a debt-to-equity ratio of -258.66.

Proteome Sciences (LON:PRM) last issued its quarterly earnings results on Thursday, April 10th. The company reported GBX (1.15) (($0.01)) earnings per share (EPS) for the quarter. Proteome Sciences had a negative return on equity of 0.01% and a negative net margin of 0.04%.

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.